Source: Investing Published 12/17/2024, 04:04
Cathie Wood’s ARK ETFs made notable moves in the stock market on Monday, December 16, 2024, completing significant deals that may interest investors. The daily trading report reveals continued focus on the genomic health sector, with ARK’s largest trade by dollar value being the purchase of 96,243 shares of Intellia Therapeutics Inc (NASDAQ:NTLA), worth $1,241,534.
The move is in line with ARK’s positive stance on the gene-editing company, having also bought shares in previous trading sessions. Additionally, ARK increased its stake in Pacific Biosciences of California Inc (NASDAQ:PACB) by purchasing 274,940 shares, for a total value of $538,882. This investment is in line with ARK’s trend of backing companies involved in genomics and biotechnology innovation.
In terms of sales, ARK reduced its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by selling 18,932 shares, for a total of $693,100. This continues the pattern of selling seen in the previous week, indicating a strategic shift away from the pharmaceutical company.
A smaller transaction involved the sale of just 100 shares of Markforged Holding Corp (NYSE:MKFG), split equally between the ARKQ and ARKX exchange-traded funds, for a total value of $415. While the amount is small, it is noteworthy as it follows a similar sale from the previous Tuesday.
On the other hand, ARK showed increased interest in Beam Therapeutics Inc (NASDAQ:BEAM), buying a total of 36,679 shares across its ARKK and ARKG ETFs, worth $1,024,444. This transaction adds to the accumulation trend seen on the previous Friday, indicating ARK’s growing belief in the company’s potential.
Investors who follow ARK’s trading patterns may find these transactions a sign of Cathie Wood’s strategic bets in the rapidly evolving biotechnology sector. As ARK continues to adjust its positions, market watchers will undoubtedly continue to closely monitor these developments to assess the future direction of the ETFs.
